QCG
TCRT icon

Quadrant Capital Group’s Alaunos Therapeutics TCRT Stock Holding History

Quadrant Capital Group’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12
Closed -$2K – 2689
2021
Q4 		$2K Buy
12
+10
+500% +$2.2K ﹤0.01% 2187
2021
Q3 		$0 Buy
+2
New +$612 ﹤0.01% 2644

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Quadrant Capital Group's TCRT Position: Q1 2022 in Review

Quadrant Capital Group sold out of Alaunos Therapeutics (TCRT) in Q1 2022, closing a stake of 12 shares — an estimated $2K sold.

Quadrant Capital Group first reported a position in TCRT in Q3 2021 and held it in 2 quarters. The position peaked at $2K in Q4 2021. 148 funds tracked by Wall St. Rank hold TCRT as of Q1 2022.

  • Quadrant Capital Group reported no remaining Alaunos Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Quadrant Capital Group sold 12 Alaunos Therapeutics shares in Q1 2022, an estimated $2K.
  • Quadrant Capital Group first reported a position in Alaunos Therapeutics in Q3 2021 and held it in 2 quarters.
  • Quadrant Capital Group's Alaunos Therapeutics position peaked at $2K in Q4 2021.
  • 148 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2022.

Based on Quadrant Capital Group's 13F filing for Q1 2022, filed 6 May 2022.